Organon & Co | OGN - Equity Capital And Reserves


Organon & Co reported $906M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Celltrion KRW 16.7T 182.36B Sep/2025
Cspc Pharmaceutical CNY 33.25B 984.93M Jun/2025
Deva Holding AS TRY 5.79B 604.07M Sep/2023
Dianthus Therapeutics USD 546.45M 243.38M Sep/2025
Divis Laboratories Ltd INR 154.13B 4.44B Sep/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
Glaxosmithkline GBP 21.7B 7.35B Sep/2025
Kangmei Pharma CNY 7.22B 504.3M Sep/2025
Knight Therapeutics CAD 773.91M 11.11M Sep/2024
Laboratorios Farma EUR 539.39M 22.74M Dec/2023
Malin Corporation EUR 193.2M 75M Dec/2024
Medical Developments International AUD 55.1M 229K Jun/2025
Merck USD 51.85B 2.79B Sep/2025
Neuren Pharmaceuticals AUD 323.27M 40.63M Jun/2025
Novartis USD 44.33B 2.28B Sep/2025
Organigram Holdings CAD 349.13M 36.37M Sep/2025
Organon & Co USD 906M 173M Sep/2025
Ovoca Bio EUR 8.67M 4.76M Jun/2022
Pharma Mar EUR 197.51M 4.02M Sep/2025
Qiagen NV USD 3.78B 128.73M Dec/2025
Sartorius EUR 2.67B 9.9M Sep/2025
Sino Biopharmaceutical CNY 34B 1.48B Jun/2025
Tilray USD 1.51B 1.22B Mar/2025